

Grifols shareholders approve all agenda items at 2024 Annual General Meeting

- All the resolutions submitted for voting obtain approval.
- These include the appointment of Nacho Abia and Albert Grifols Coma-Cros as board directors, and Anne-Catherine Berner and Claire Giraut as independent directors.
- FY2023 was a record year for the company, exceeding commitments and marking a solid progression of operating and financial results, reaching 6,592 million euros in revenues and adjusted EBITDA of 1,474 million euros.
- Grifols reiterates its focus on cash flow generation and deleveraging reduction, with the upcoming closing and sale of its 20% stake in Shanghai RAAS to Haier Group for EUR 1.6 billion.

Barcelona, June 14, 2024.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leader in the production of plasma-derived medicines, today announced that at its 2024 Annual General Meeting shareholders have approved all proposed resolutions including electing Nacho Abia and Albert Grifols Coma-Cros as directors and appointing Anne-Catherine Berner and Claire Giraut as independent directors to the company's Board of Directors.

The meeting was represented by a total of 511 shareholders, holders of 238.439.950 Class A shares, representing 55,95% of the company's share capital with voting rights. They ratified support for Grifols' 2024 commitments to strengthening operational efficiency, enhancing corporate governance, reducing debt and creating value for all shareholders.

Shareholders voted also to:

- Increase the number of members of the Board of Directors to 13.
- Re-elect the company's independent auditors for fiscal years 2024-2026 and appoint Deloitte as auditor of sustainability information.
- Approve the company's individual and consolidated financial statements, as well as the consolidated statement of non-financial information.
- Approve, on a consultative basis, the Annual Compensation Report.
- Modify the remuneration policy of the company's directors.

Grifols Executive Chairman, Thomas Glanzmann, presented the results for 2023 in which the company closed a record year – and exceeded forecasts – reaching 6,592 million euros in revenues (+10.9% at constant exchange rates), adjusted EBITDA of 1,474 million euros (+26.3% at constant exchange rates) and net profit of 56 million euros. In addition, the company confirmed that it is on track to meet the guidance set for 2024.

GRIFOLS

"2023 was marked by our strong operating and financial results and the strengthening of our corporate governance and management team" **Thomas Glanzmann** said. "We now look forward to Nacho Abia leading Grifols into the future and we also welcome Anne-Catherine Berner and Claire Giraut to our Board. We sincerely thank Raimon Grifols and Victor Grifols for their leadership and valuable contributions to the company's growth over the past years as they now transition to their roles as proprietary Directors. The values that have made this company exceptional for over a century will continue to be the hallmark of Grifols. The Board and management team are confident in Grifols' future and committed to the continued execution of our mission to improving patient lives."

In his remarks at the annual meeting, CEO **Nacho Abia** highlighted Grifols strengths, its solid fundamentals, the transformation process and changes carried out in recent quarters, as well as the potential of the investments made.

"We are now poised to enter a new phase of growth and my management priorities are very clear: to increase cash generation, reduce financial debt, accelerate profitable growth, enhance innovation and improve operating efficiency, all with the ultimate goal of providing continued, strong value to all our shareholders".

Full commitment to Sustainability and ESG

Shareholders endorsed the company's ESG performance and key milestones, as well as its non-financial reporting and sustainability indicators.

To this end, the group's 23,747 associates, comprised of individuals from 92 nationalities, more than half of whom were women, carried out essential work, making it possible to produce and distribute plasma medicines responsibly and ethically. This enabled Grifols to generate value beyond economic profit, with EUR 32,427 million going towards social impact in 2023, including EUR 5,057 million for donors and donor communities and EUR 27,370 million for patients.

In addition, Grifols' has made solid progress in achieving the goals laid out in the Grifols 2030 Agenda- an ambitious roadmap for the coming years focused on 30 corporate objectives based on the six strategic pillars of the Master Sustainability Plan- reaching a degree of compliance of over 90% in its intermediate objectives.

For additional information, visit [Grifols AGM](#) and [Grifols Annual Integrated and Sustainability Report 2023](#)

INVESTORS:

Grifols Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

Duomo Comunicación – Grifols Press Office

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel. +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel. +34 650 402 225

Grifols Media Press Office

media@grifols.com

Tel. +34 93 571 00 02

GRIFOLS

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

